| miRNA | Treatment | Verified targets in CRC | References |
| miRNAs overexpressed in chemoresistance to conventional drugs | Let-7g | S-1 | RAS, cyclin D, c-Myc, E2F, cytochrome c | [177] | miR-10b | 5-FU | BIM | [178] | miR-19b | 5-FU | SFPQ, MYBL2 | [179] | miR-20a | 5-FU, oxaliplatin | BNIP2 | [180] | miR-23a | 5-FU | APAF-1 | [181] | miR-31 | 5-FU | ? | [182] | miR-140 | 5-FU | HDAC | [183] | miR-148a | 5-FU, oxaliplatin | ? | [184] | miR-181b | S-15-FU | RAS, cyclin D, c-Myc, E2F, cytochrome c | [177] | miR192/215 | 5-FU | TYMS, DHFR | [185, 186] | miR-203 | Oxaliplatin | ATM | [187] | miR-224 | 5-FU | ? | [188] | miR-520g | 5-FU, oxaliplatin | CDKNIA (p21) | [189] | miR-625-3p | Oxaliplatin | ? | [190] |
| miRNAs downregulated in chemoresistance to conventional drugs | miR-22 | 5-FU | BTG1 | [191] | miR-34a | 5-FU | SIRT1, E2F3, KIT, LDHA | [192ā194] | miR-122 | 5-FU | PKM2 | [195] | miR-129 | 5-FU | BCL2, TYMS, E2F3 | [196] | miR-133a | Oxaliplatin | RFFL | [197] | miR-139-5p | 5-FU | NOTCH1 | [198] | miR-141/200c | Oxaliplatin | ZEB1 | [199] | miR-143 | 5-FU, oxaliplatin | BCL2, NFKB, ERK5, IGF1R | [200, 201] | miR145 | 5-FU | FLI-1, RAD18 | [202, 203] | miR-149 | 5-FU | FOXM1 | [204] | miR-153 | Oxaliplatin | FOXO3 | [205] | miR-196a | Oxaliplatin | HOXA7, HOXB8, HOXC8, HOXD8 | [206] | miR-200 cluster | 5-FU | EMT-related genes | [207] | miR203 | 5-FU | TYMS | [208] | miR-204 | 5-FU | HMGA2 | [209] | miR-222 | Oxaliplatin | ADAM17 | [188] | miR-297 | Oxaliplatin | ABCC2 | [210] | miR-451 | Irinotecan | ABCC1 | [211] | miR-497 | 5-FU, irinotecan | IGF1R | [212] | miR-519c | 5-FU, oxaliplatin | ABCG2, ELAVL1 (HuR) | [213] | miR-1915 | Oxaliplatin | BCL2 | [214] |
| miRNAs overexpressed in chemoresistance to monoclonal antibody-based therapies | miR-17-3p | Cetuximab | ? | [215] | miR-31 | Cetuximab | ? | [216] | miR-126 | Bevacizumab, XELOX | ? | [217] | miR-146-3p | Cetuximab | IL1A | [215] | miR-199a-5p/375 | Cetuximab | PHLPP1 | [218] | miR-486-5p | Cetuximab | ARHGAP5, ST5, DOCK3, TOB1, PIK3R1 | [215] |
| miRNAs downregulated in chemoresistance to monoclonal antibody-based therapies | Let-7 family | Cetuximab, panitumumab | KRAS | [215, 219] | miR-7 | Cetuximab | EGFR, RAF1, ERK1/2, AKT | [136] |
|
|